What is Quantum-Si?
Founded in 2013, Quantum-Si is at the forefront of protein sequencing technology, developing and manufacturing advanced testing equipment. Their innovative platform is designed to empower research laboratories globally with molecular-level protein analysis capabilities, thereby accelerating biological discoveries and advancements in human health research. As a publicly traded entity on Nasdaq, Quantum-Si operates within the dynamic life sciences and medical technology industries, providing critical tools for scientific research and development.
How much funding has Quantum-Si raised?
Quantum-Si has raised a total of $100.3M across 2 funding rounds:
Debt
$350K
Stock/Share Issuance
$100M
Debt (2020): $350K with participation from PPP
Stock/Share Issuance (2025): $100M, investors not publicly disclosed
Key Investors in Quantum-Si
PPP
Public-Private Partnership
What's next for Quantum-Si?
The recent major strategic investment signifies a pivotal moment for Quantum-Si, likely enabling the company to scale its operations, enhance its product development pipeline, and expand its market reach. This strategic backing suggests a focus on accelerating the democratization of protein sequencing, potentially leading to new breakthroughs in diagnostics and therapeutic research. The company's trajectory indicates a strong emphasis on innovation and market penetration within the competitive biotechnology landscape.
See full Quantum-Si company page
